• Tatsuya Nakamura, Takeshi Kodaira, Hiroyuki Tachibana, Natsuo Tomita, Takuya Tomoda, Rie Nakahara, Haruo Inokuchi, Nobutaka Mizoguchi, Akinori Takada, and Nobukazu Fuwa.
• Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. tatsuya.nakamura@nifty.com
• Jpn. J. Clin. Oncol. 2008 Dec 1; 38 (12): 803-9.

ObjectiveTo evaluate the treatment outcome of patients with locally recurrent nasopharyngeal carcinoma (NPC) treated with re-irradiation and chemotherapy.MethodsBetween 1991 and 2004, 36 patients with locally recurrent NPC received re-irradiation and chemotherapy. The median re-irradiation dose was 37.9 Gy; the median total dose of prior irradiation and re-irradiation was 104.4 Gy. The outcome is studied retrospectively and also evaluated the prognostic factors and toxicities.ResultsWith a median follow-up of 40 months, 3-year overall survival (OS) was 58.3% and 3-year progression-free survival (PFS) was 25.0%. Patients aged <50 and of early stage at recurrence had a significantly better OS and PFS. Over Grade 3 of late toxicities were seen in patients received a total dose of >110 Gy.ConclusionsAge and stage at recurrence were identified as prognostic factors for OS and PFS. Patients received external beam radiation therapy at a total dose of more than 110 Gy should be careful for severe late toxicities, and it is thought to be the optimal dose for recurrent tumor.

42 keywords...

hide…